Top Markets
#1 Akedo Akedo +62.25%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +50.06%
#4 Velvet Velvet +40.81%
#5 Black Phoenix Black Phoenix +34.48%
#6 Ο„emplar Ο„emplar +27.84%
#7 Ribbita by Virtuals Ribbita by Virtuals +20.04%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +18.68%
#9 Bitway Bitway +17.34%
#10 Cap Cap +16.41%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Algernon Pharmaceuticals Inc. Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals Inc.

AGN
Rank in Stocks #38375
Algernon Pharmaceuticals Inc. is a clinical-stage pharmaceutical company... Algernon Pharmaceuticals Inc. is a clinical-stage pharmaceutical company dedicated to discovering and developing new treatments. Their research and development efforts concentrate on a range of serious conditions, including non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19, operating across Canada and Australia. The company's primary drug candidate, NP-120, acts as an N-methyl-d-aspartate (NMDA) receptor glutamate antagonist. This compound specifically targets the NMDA-type subunit 2B (Glu2NB) and also demonstrates agonist activity for the Sigma-1 receptor, a chaperone protein elevated during endoplasmic reticulum stress. Furthermore, Algernon is advancing AP-188, a psychedelic agent from the tryptamine family, for treating ischemic stroke in humans. Preclinical investigations for AP-188, as part of their stroke clinical research program, are underway through a collaboration with Charles River Laboratories. Established in 2015, Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.
Share Price
$0.29357476
Last synced: 2026-05-14
Market Cap
$1.02M
Change (1 day)
1.27%
Change (1 year)
-42.07%
Country
CA
Trade Algernon Pharmaceuticals Inc. (AGN)

Category

Healthcare
P/E ratio for Algernon Pharmaceuticals Inc. (AGN)
P/E ratio as of 2026 TTM: 0
According to Algernon Pharmaceuticals Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Algernon Pharmaceuticals Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.